| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2026 ( Subtotal = $74,818,150 ) (Continued on the next page) |
| | 2026 | 2026 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | R01AG075583 | Blood-Brain Barrier Repair in Alzheimer’s Disease with Epilepsy | 000 | 5 | NIH | 6/5/2026 | $719,390 |
| | 2026 | 2026 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | R01MH134859 | Neural Mechanisms of Menstrual Cycle Effects on ADHD and Cognition | 000 | 3 | NIH | 4/21/2026 | $736,038 |
| | 2026 | 2026 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | R25CA302429 | Markey STRONG Scholars Program | 000 | 2 | NIH | 6/19/2026 | $223,823 |
| | 2026 | 2026 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | R01AR084850 | Regulation of Myonuclear Turnover Dynamics in Multinucleated Muscle Cells | 000 | 2 | NIH | 6/12/2026 | $529,010 |
| | 2026 | 2026 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | R00DA056288 | Neurocognitive Impairments Resulting from Adolescent Prescription Opioid Use Disorder: Longitudinal Impact, Neural Mechanisms, and Comorbidities | 000 | 5 | NIH | 3/19/2026 | $249,000 |
| | 2026 | 2026 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | R01ES030380 | Radon on the RADAR | 001 | 8 | NIH | 5/26/2026 | $514,461 |
| | 2026 | 2026 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | R01NS122028 | Reduced BBB Water Exchange as a Preclinical Biomarker of Small Vessel Disease | 001 | 3 | NIH | 3/5/2026 | $58,999 |
| | 2026 | 2026 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | R01NS122028 | Reduced BBB Water Exchange as a Preclinical Biomarker of Small Vessel Disease | 000 | 3 | NIH | 1/30/2026 | $530,998 |
| | 2026 | 2026 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | R01HD116735 | Harnessing the inflammatory response to promote regeneration in mammals | 000 | 2 | NIH | 4/27/2026 | $657,560 |
| | 2026 | 2026 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | R61HL177474 | Liposomal azithromycin to treat cardiac inflammation | 001 | 2 | NIH | 4/27/2026 | $2,048 |
| | 2026 | 2026 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | R61HL177474 | Liposomal azithromycin to treat cardiac inflammation | 000 | 2 | NIH | 4/3/2026 | $522,854 |
| | 2026 | 2026 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | R01DA054347 | Cannabis Modulation of Outcomes Related to Opioid Use Disorder: Opioid Withdrawal, Opioid Abuse Potential and Opioid Safety | 001 | 4 | NIH | 2/6/2026 | $67,776 |
| | 2026 | 2026 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | R01DA054347 | Cannabis Modulation of Outcomes Related to Opioid Use Disorder: Opioid Withdrawal, Opioid Abuse Potential and Opioid Safety | 000 | 4 | NIH | 1/26/2026 | $610,002 |
| | 2026 | 2026 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | T32AA027488 | Interdisciplinary Training in Alcohol Research | 000 | 8 | NIH | 4/21/2026 | $172,616 |
| | 2026 | 2026 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | R01DA063069 | Targeting Immune Inflammation in Cocaine Use Disorder: A Human Laboratory Study with Pentoxifylline | 000 | 2 | NIH | 3/3/2026 | $612,820 |
| | 2026 | 2026 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | R21CA301113 | Pathways to Prevention: Exploring Social Determinants of Health in Early Onset Colorectal Cancer | 000 | 2 | NIH | 4/2/2026 | $215,985 |
| | 2026 | 2026 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | R01DA033862 | Examining the Impact of the Twin Epidemics of Methamphetamine and Opioid Use on Overdose, Risky Sex and Treatment Engagement among PWUD in Two Rural Appalachian Cohorts | 000 | 12 | NIH | 1/29/2026 | $482,290 |
| | 2026 | 2026 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | P50MD019476 | UK ASCEND (Achieving Success in Community-Engaged research to elimiNate Disparities) | 000 | 3 | NIH | 6/1/2026 | $598,149 |
| | 2026 | 2026 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | P40OD019794 | Ambystoma Genetic Stock Center | 002 | 12 | NIH | 4/27/2026 | $146,682 |
| | 2026 | 2026 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | P40OD019794 | Ambystoma Genetic Stock Center | 001 | 12 | NIH | 3/19/2026 | $464,493 |
| | 2026 | 2026 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | R01CA284532 | Fatty Acid Synthase as a Novel Molecular Target for Colon Cancer Treatment | 000 | 3 | NIH | 2/27/2026 | $402,968 |
| | 2026 | 2026 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | R01AG081608 | Molecular genetics of human age-related hearing loss | 001 | 4 | NIH | 3/10/2026 | $587,270 |
| | 2026 | 2026 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | R01DA062746 | Impact of Cannabis on Opioid Self-Administration: Determining if Cannabis Alters the Drive to Take Opioids in Individuals with Opioid Use Disorder | 000 | 1 | NIH | 2/4/2026 | $647,142 |
| | 2026 | 2026 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | F30AG099336 | Selective Targeting of Myeloid-derived APOE to improve safety and efficacy of anti-amyloid antibody therapy in Alzheimer’s Disease | 000 | 1 | NIH | 6/18/2026 | $38,914 |
| | 2026 | 2026 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | R01NS142462 | Improving Disease-Modifying Therapy Uptake among Patients with Multiple Sclerosis | 000 | 1 | NIH | 6/19/2026 | $662,969 |
| | 2026 | 2026 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | R34CA313778 | Planning grant to support a future trial of an intervention to improve clinical trial education and enrollment | 000 | 1 | NIH | 6/19/2026 | $281,820 |
| | 2026 | 2026 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | R00CA249048 | A pro-metastatic secretory program activated by epithelial-to-mesenchymal transition | 000 | 5 | NIH | 3/2/2026 | $249,000 |
| | 2026 | 2026 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | R01HL168085 | Development of a Percutaneous Double Lumen Cannula-Based Cavopulmonary Assist System Toward Clinical Application | 000 | 3 | NIH | 4/27/2026 | $643,810 |
| | 2026 | 2026 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | R01AG084670 | Emerging role of PAD4 mediated TDP-43 citrullination in the neuropathology of LATE and Alzheimer’s Disease Related Dementias | 001 | 3 | NIH | 2/26/2026 | $65,020 |
| | 2026 | 2026 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | R01AG084670 | Emerging role of PAD4 mediated TDP-43 citrullination in the neuropathology of LATE and Alzheimer’s Disease Related Dementias | 000 | 3 | NIH | 1/19/2026 | $585,180 |
| | 2026 | 2026 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | R01DK113625 | Contributions of Hepatic and Intestinal Pathways to Cholesterol Excretion | 000 | 9 | NIH | 3/5/2026 | $491,578 |
| | 2026 | 2026 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | R01AR084282 | Using the gut microbiome to treat skeletal muscle atrophy | 001 | 2 | NIH | 5/14/2026 | $22,197 |
| | 2026 | 2026 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | R01AR084282 | Using the gut microbiome to treat skeletal muscle atrophy | 000 | 2 | NIH | 1/16/2026 | $399,502 |
| | 2026 | 2026 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | R01HL171111 | Functional Interactions Between Lipoproteins and Protease Inhibitors in Atherosclerosis | 000 | 3 | NIH | 5/11/2026 | $628,345 |
| | 2026 | 2026 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | R35GM155281 | Cellular and Molecular Determinants of Post-Burn Myopathy | 000 | 3 | NIH | 5/22/2026 | $378,407 |
| | 2026 | 2026 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | R01ES034786 | Mechanisms of Sex-specific Metabolic Disruption Caused by Organophosphate Flame Retardant Exposure | 000 | 3 | NIH | 6/26/2026 | $472,702 |
| | 2026 | 2026 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | U01DK135111 | Restoration of Impaired Awareness of Hypoglycemia U01 Consortium: University of Kentucky | 000 | 4 | NIH | 2/2/2026 | $790,957 |
| | 2026 | 2026 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | R01AG084180 | Impacting Inflammation through Mechanistic Target of Rapamycin (imTOR) | 000 | 3 | NIH | 5/26/2026 | $611,775 |
| | 2026 | 2026 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | R01DA060632 | Advancing Troriluzole as a Treatment for Methamphetamine Use Disorder: A Human Laboratory Study | 000 | 2 | NIH | 3/3/2026 | $621,805 |
| | 2026 | 2026 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | R01HL172813 | Circadian Regulation of Cardiac Electrophysiology | 000 | 3 | NIH | 5/12/2026 | $669,467 |
| | 2026 | 2026 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | F31AG087618 | Using the gut microbiome to treat disuse atrophy in aging. | 001 | 2 | NIH | 3/25/2026 | $576 |
| | 2026 | 2026 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | R21NS147149 | Repetitive Mild TBI and Physiological Stress as Catalysts for Chronic Neurovascular Dysfunction | 000 | 1 | NIH | 1/26/2026 | $192,500 |
| | 2026 | 2026 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | R03CA308625 | Fatty Acid Synthase Driven Exosome Secretion in Colorectal Cancer Metastasis | 000 | 1 | NIH | 6/9/2026 | $154,000 |
| | 2026 | 2026 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | R21CA307890 | Single Cell-Resolution Imaging of Drug Resistance via Toxic Metal Pre-exposure in Lung Patient Tumor Microenvironment | 000 | 1 | NIH | 6/12/2026 | $395,973 |
| | 2026 | 2026 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | R01AG093616 | Evaluation of Noninvasive Muscle Imaging Biomarkers for Knee Osteoarthritis in Older Adults | 000 | 1 | NIH | 1/23/2026 | $666,504 |
| | 2026 | 2026 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | RM1DA064496 | Kentucky Women's Justice Community Overdose Innovation Network - Phase II | 002 | 2 | NIH | 6/30/2026 | $1,439,775 |
| | 2026 | 2026 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | R01DK140312 | Targeting Intracellular Cholesterol Distribution: Mechanisms and Therapeutic Strategies for Metabolic dysfunction-associated steatotic liver disease (MASLD) | 000 | 1 | NIH | 3/11/2026 | $707,062 |
| | 2026 | 2026 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | R21DA064350 | Dual Enkephalinase Inhibitor-Based Therapy in Offspring with Prenatal Fentanyl Exposure | 000 | 1 | NIH | 5/19/2026 | $432,754 |
| | 2026 | 2026 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | R21AG098743 | Arginine Sensor (CASTOR1) Dysfunction Drives Tauopathy | 000 | 1 | NIH | 1/21/2026 | $423,500 |
|
